Literature DB >> 17417784

hOGG1 Ser326Cys polymorphism and susceptibility to gallbladder cancer in a Chinese population.

Xingyuan Jiao1, Jiefu Huang, Shengli Wu, Mingde Lv, Yize Hu, Xiaokang Su, Canqiao Luo, Broelsch Ce.   

Abstract

The human oxoguanine glycosylase 1(hOGG1) gene encodes a DNA glycosylase that is involved in excision repair of 8-OH-dG (8-hydroxy-2-deoxyguanine) from oxidatively-damaged DNA. To determine whether hOGG1 plays a role in the risk for adenocarcinoma of the gallbladder, we tested the association of this polymorphism with gallbladder cancer in a Chinese population-based, case control study of 204 cases and 209 controls. The subjects were genotyped with a polymerase chain reaction-restriction fragment length polymorphism (PCR-RELP) assay. The association between the genetic polymorphism of this gene and risk of the cancer was examined by using a multivariate analysis. We found that the distribution of hOGG1 Ser326Cys genotypes among controls (Ser/Ser, 37.3%; Ser/Cys, 53.6% and Cys/Cys, 9.1%) was significantly different from that among gallbladder cancer cases (Ser/Ser, 43.1%; Ser/Cys, 36.3% and Cys/Cys, 20.6%). Significantly increased risk for gallbladder cancer was both the hOGG1 326Ser/Cys (Odds ratio [OR] = 1.9, 95% confidence interval (CI) = 1.0-3.7) and hOGG1 326Cys/Cys genotypes (OR = 4.5, 95% CI = 1.1-22.4). We observed no statistically significant association between hOGG1 genotype and gallbladder cancer association in gallstone absence. In contrast, a near-significant increase in risk for gallbladder cancer was observed for gallstone presence with the hOGG1 326Ser/Cys genotype (OR = 2.2, CI = 1.4-3.5) whereas a significant increase in association for gallbladder cancer was observed for gallstone presence with the 326Cys/Cys genotype (OR = 6.1, CI = 2.1-27.2). These data corresponded with the fact that a significant trend towards increased association for gallbladder cancer was observed with potentially higher-risk hOGG1 genotypes in gallstone presence(p < 0.001, chi(2) trend test)but not in gallstone absence(p = 0.89, chi(2) trend test). A significant increase in risk for gallbladder cancer was observed for larger gallstone (those with stone diameters 2 cm or greater) with the hOGG1 326Ser/Cys(OR = 1.9, 95% CI = 1.1-2.9) and hOGG1 326Cys/Cys genotypes(OR = 5.9, 95% CI = 1.6-18.0). These data are consistent with the observation that a significant trend towards increased risk for gallbladder cancer was observed with potentially higher-risk hOGG1 genotypes in gallbladder cancer patients with larger gallstone (p < 0.001, chi(2) trend test). However, we observed no statistically significant association between hOGG1 genotype and gallbladder cancer risk in gallbladder cancer patients with smaller gallstone (those with stone diameters 2 cm smaller) (hOGG1 326Ser/Cys:OR = 2.2, 95% CI = 0.8-4.0; hOGG1 326Cys/Cys:OR = 2.9, 95% CI = 0.6-29.4; p = 0.06, chi(2) tread test). These results suggest that hOGG1 Ser326Cys polymorphism is associated with gallbladder cancer risk. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17417784     DOI: 10.1002/ijc.22748

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  The inflammatory inception of gallbladder cancer.

Authors:  Jaime A Espinoza; Carolina Bizama; Patricia García; Catterina Ferreccio; Milind Javle; Juan F Miquel; Jill Koshiol; Juan C Roa
Journal:  Biochim Biophys Acta       Date:  2016-03-12

Review 2.  Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis.

Authors:  Kshitij Srivastava; Anvesha Srivastava; Kiran Lata Sharma; Balraj Mittal
Journal:  Mutat Res       Date:  2011-06-25       Impact factor: 2.433

3.  Novel mechanism of regulation of the DNA repair enzyme OGG1 in tuberin-deficient cells.

Authors:  Samy L Habib; Besant K Bhandari; Nahed Sadek; Sherry L Abboud-Werner; Hanna E Abboud
Journal:  Carcinogenesis       Date:  2010-09-13       Impact factor: 4.944

4.  HOGG1 polymorphism in atrophic gastritis and gastric cancer after Helicobacter pylori eradication.

Authors:  Lei-Min Sun; Yan Shang; Ya-Min Zeng; Yan-Yong Deng; Jian-Feng Cheng
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

5.  The hOGG1 Ser326Cys polymorphism contributes to digestive system cancer susceptibility: evidence from 48 case-control studies.

Authors:  Yang Wang; Xujie Gao; Feng Wei; Xinwei Zhang; Jinpu Yu; Hua Zhao; Qian Sun; Fan Yan; Cihui Yan; Hui Li; Xiubao Ren
Journal:  Tumour Biol       Date:  2014-10-17

6.  Generation of 3'-OH terminal-triggered encoding of multicolor fluorescence for simultaneous detection of different DNA glycosylases.

Authors:  Huige Zhang; Zixi Gao; Fei He; Jingfeng Lan; Hailong Chai; Shiqian Zhang; Xianwei Zuo; Hongli Chen; Xingguo Chen
Journal:  Anal Bioanal Chem       Date:  2022-08-19       Impact factor: 4.478

7.  Sequencing and analysis of a South Asian-Indian personal genome.

Authors:  Ravi Gupta; Aakrosh Ratan; Changanamkandath Rajesh; Rong Chen; Hie Lim Kim; Richard Burhans; Webb Miller; Sam Santhosh; Ramana V Davuluri; Atul J Butte; Stephan C Schuster; Somasekar Seshagiri; George Thomas
Journal:  BMC Genomics       Date:  2012-08-31       Impact factor: 3.969

8.  Gallbladder cancer predisposition: a multigenic approach to DNA-repair, apoptotic and inflammatory pathway genes.

Authors:  Kshitij Srivastava; Anvesha Srivastava; Ashok Kumar; Balraj Mittal
Journal:  PLoS One       Date:  2011-01-21       Impact factor: 3.240

9.  DNA damage and repair in endometrial cancer in correlation with the hOGG1 and RAD51 genes polymorphism.

Authors:  Renata Krupa; Anna Sobczuk; Tomasz Popławski; Katarzyna Wozniak; Janusz Blasiak
Journal:  Mol Biol Rep       Date:  2010-07-03       Impact factor: 2.316

10.  The effect of hOGG1 Ser326Cys polymorphism on cancer risk: evidence from a meta-analysis.

Authors:  Bingbing Wei; You Zhou; Zhuoqun Xu; Bo Xi; Huan Cheng; Jun Ruan; Ming Zhu; Qiang Hu; Qiang Wang; Zhirong Wang; Zhiqiang Yan; Ke Jin; Deqi Zhou; Feng Xuan; Xing Huang; Jianfeng Shao; Peng Lu
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.